Oncolytic Vaccinia Virus TG6002 clinical trials
Also written TG6002.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses Oncolytic Vaccinia Virus TG6002 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TG6002
- 2
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Transgene (2) · Tasly Tianjin Biopharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses Oncolytic Vaccinia Virus TG6002 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerTerminatedPhase 1/2TransgeneNCT04194034Written as TG6002How we know
- Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.TerminatedPhase 1/2TransgeneNCT03724071Written as TG6002How we know
- Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1/2Tasly Tianjin Biopharmaceutical Co., Ltd.NCT04226066Written as T601How we know